The emerging role of myeloid-derived suppressor cells in radiotherapy
Radiation Oncology Journal · 31.03.2020 · 38 (1) · 1-10
DOI: 10.3857/roj.2019.00640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Oncology Journal, erschienen am 31.03.2020. Verfasst von Changhee Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare, National Research Foundation of Korea.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
- National Research Foundation of Korea
- Ministry of Education
Zitieren
APA
Kang, C., Jeong, S. Y., Song, S. Y., & Choi, E. K. (2020). The emerging role of myeloid-derived suppressor cells in radiotherapy. Radiation Oncology Journal, 38(1), 1-10. https://doi.org/10.3857/roj.2019.00640
Vancouver
Kang C, Jeong SY, Song SY, Choi EK. The emerging role of myeloid-derived suppressor cells in radiotherapy. Radiation Oncology Journal. 2020;38(1):1-10. doi:10.3857/roj.2019.00640
BibTeX
@article{Kang2020,
author = {Kang, Changhee and Jeong, Seong-Yun and Song, Si Yeol and Choi, Eun Kyung},
title = {The emerging role of myeloid-derived suppressor cells in radiotherapy},
journal = {Radiation Oncology Journal},
year = {2020},
volume = {38},
number = {1},
pages = {1--10},
doi = {10.3857/roj.2019.00640}
}
EUVIMED